Louisiana ramps up price transparency efforts

State legislatures are continuing their crackdown on rising healthcare costs by putting pharmaceutical manufacturer prices under the microscope.

On June 12, 2026, Louisiana Governor Jeff Landry signed into law Senate Bill 401 (enacted as Act No. 915), significantly ramping up the state's transparency requirements.

Here is what you need to know about Louisiana's new framework, how it stacks up against neighboring Texas, and what it means for the state's existing reporting landscape.

Summary of Louisiana SB 401 Requirements

Louisiana’s new law creates a Prescription Drug Affordability Board (PDAB)-centered transparency framework within the Department of Insurance and adds new manufacturer reporting obligations. The key components include:

• Annual Pricing Disclosures: By January 15 of each year, drug manufacturers must submit current Wholesale Acquisition Cost (WAC) information for all FDA-approved prescription drugs sold in the state.
• Price Increase Triggers: If a drug costing at least $100 for a 30-day supply sees a WAC increase of 15% or more in a single year or 40% or more over a rolling three-year period, manufacturers must flag it. They must submit a report within 30 days of the effective date explaining the exact factors driving the increase.
• Targeted Deep Dives: Every year by June 1, the newly formed board will select up to 10 high-spend prescription drugs to undergo an intensive review, requiring manufacturers to hand over specific company-level R&D and capital expenditure data.
• Public Transparency Webpage: The state will host a consumer-facing webpage featuring a prominent, dedicated link on the Department of Insurance homepage to display public prescription drug pricing data.

Compare & Contrast: Louisiana vs. Texas (HB 1033)When comparing Louisiana's SB 401 to Texas’s drug transparency law, the text reveals a few identical mechanisms alongside completely different enforcement philosophies.

The Similarities

• Identical Triggers & Timelines: Both states utilize the exact same mathematical benchmarks for price increases (15% in one year / 40% over three years for drugs over $100).
• Submission Deadlines: Both Louisiana and Texas set their annual WAC report deadlines for January 15.
• Penalties: Both states enforce compliance via an administrative penalty of up to $1,000 per day for each violation.
• Brands and Generics: Both states include reporting requirements for both brands and generic drugs.
  
• Who is Required to Report: Louisiana and Texas law both cast a wide net across the supply chain, requiring annual transparency reports from Pharmacy Benefit Managers (PBMs) and health benefit plan issuers regarding aggregated rebates and spending metrics (in addition to these requirements on the manufacturers).

The Differences

• The Oversight Body: Louisiana creates a dedicated, multi-member Prescription Drug Affordability Board tasked with actively analyzing drug classes and recommending cost-containment measures. Texas relies on its standard health department structure without a specialized board.
• Targeted Audits: Louisiana's board proactively isolates 10 high-impact drugs per year for detailed financial scrutiny. Texas lacks this targeted "top 10" auditing mandate.
• Administrative Fees: Texas requires manufacturers to submit an administrative fee (capped at $400) with their reports to fund the program. Louisiana's text does not outline an upfront filing fee for its submissions.

How SB 401 Impacts Current Louisiana Reporting

Louisiana has previously adjusted its laws surrounding drug costs, but SB 401 completely modernizes the state's approach by shifting from passive data collection to active, centralized accountability.

While older laws or historical quarterly WAC tracking focused primarily on static price logs, SB 401 introduces a multi-layered oversight system. It adds teeth to the state's regulatory framework by establishing a dedicated board to investigate the underlying "drivers" of those costs, launching an open-access public webpage for consumer awareness, and imposing strict 30-day notice requirements on triggering price increases.

Importantly, Section 3 of the new act explicitly cleans up the statutory books by repealing R.S. 22:1870(B)(5) to make way for this robust new standard. This is significant because in addition to creating a different price increase requirement, effective January 1, 2027, it ELIMINATES the requirement to provide a new drug notice to the state when introducing a new drug for distribution in this state when the wholesale acquisition cost is greater than the amount that causes the drug to be considered a specialty drug under the Medicare Part D program. Although the new drug notification requirement was proposed in earlier versions of SB 401, Senate Bill 368 would have preserved a new-drug-style reporting trigger but it remained pending in Senate Insurance and did not pass. Therefore, currently it does not appear that a new drug notice requirement will be in effect after January 1, 2027.

A Critical Compliance Note for 2027

With the law officially taking effect on January 1, 2027, manufacturers face an immediate compliance gray area. Companies will need to determine exactly how the annual reports due after that date must incorporate or disclose significant price increases that were taken prior to the law's effective date. Manufacturers should watch for Louisiana Department of Insurance rulemaking/guidance on the first January 15 annual WAC report.